PEPG: PepGen Inc. insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Institutional ownership (Q2 2026)
71 institutions reported holding $92.18M of PepGen Inc. on Form 13F (94 the quarter before). 6 opened a new position and 28 sold out. Shares held by institutions: -9%.
| Largest holders | Shares | Value |
|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 20,064,545 | $36.12M |
| Commodore Capital LP | 4,475,000 | $8.05M |
| VIKING GLOBAL INVESTORS LP | 3,482,434 | $6.27M |
| Laurion Capital Management LP | 2,750,855 | $4.95M |
| ADAR1 Capital Management, LLC | 2,591,085 | $4.66M |
| Vivo Capital, LLC | 2,325,000 | $4.18M |
| VANGUARD CAPITAL MANAGEMENT LLC | 1,935,920 | $3.48M |
| MILLENNIUM MANAGEMENT LLC | 1,786,765 | $3.22M |
| RENAISSANCE TECHNOLOGIES LLC | 1,520,246 | $2.74M |
| BlackRock, Inc. | 1,304,262 | $2.35M |
Clinical trial readouts
1 Phase 2 or 3 trials by PepGen Inc. with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2027-03 (est.) | PGN-EDODM1 | Myotonic Dystrophy 1 | Phase 2 | 24 | Recruiting | NCT06667453 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.